PitchSend

argenx SE Investor Day Presentation Deck

2021: Reaching Myasthenia Gravis Patients with Efgartigimod New modality nature biotechnology FcRn. Only Fc fragment targeting FcRn Designed ADAPT with patient input adapt myasthenia gravis study MG-ADL Change from Baseline 0 -1 -5 -6 Defined disease biology -80 Correlation of total IgG and MG ADL Engaging MG community -70 -60 SP -50 -40 -30 IgG Percent Change from Baseline -20 -10 0 8

View entire presentation